UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

Annals of oncology, 2012-06, Vol.23 (6), p.1555-1561

2012

Volltextzugriff (PDF)

Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia

Annals of oncology, 2012-09, Vol.23 (9), p.2386-2390

2012

Volltextzugriff (PDF)

81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES

Leukemia research, 2015-04, Vol.39, p.S39-S40

2015

Volltextzugriff (PDF)

P640 Fatal viral opportunistic infections and Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment for a refractory Sezary syndrome

International journal of antimicrobial agents, 2007, Vol.29, p.S150-S151

2007

Volltextzugriff (PDF)

Paraneoplastic Acute Diffuse Encephalitis Revealing Hodgkin's Disease

Leukemia & lymphoma, 2004-12, Vol.45 (12), p.2509-2512

2004

Volltextzugriff (PDF)

Hémorragies multiples inattendues chez un patient sous anticoagulants

La revue de medecine interne, 2016-12, Vol.37, p.A192-A192

2016

Volltextzugriff (PDF)

Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

Intensive care medicine, 2017-11, Vol.43 (11), p.1613-1625

2017

Volltextzugriff (PDF)

PS993 DE NOVO ADULT ACUTE MYELOID LEUKEMIA PATIENTS DISPLAY AT DIAGNOSIS FUNCTIONAL DEREGULATION OF REDOX BALANCE CORRELATED WITH MOLECULAR SUBTYPES AND OVERALL SURVIVAL

HemaSphere, 2019-06, Vol.3 (S1), p.446-447

2019

Volltextzugriff (PDF)

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

Haematologica (Roma), 2010-06, Vol.95 (6), p.892-899

2010

Volltextzugriff (PDF)

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM

Blood, 2007-11, Vol.110 (11), p.1453-1453

2007

Volltextzugriff (PDF)

Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia

Annals of oncology, 2012-09, Vol.23 (9), p.2386

2012

Volltextzugriff (PDF)

Maladie de Hodgkin de localisation orbitaire : à propos d'un cas

Cancer radiothérapie, 2006-11, Vol.10 (6), p.532-533

2006

Volltextzugriff (PDF)

Value of Early Evaluation with FDG-PET for Follicular Lymphoma

Blood, 2005-11, Vol.106 (11), p.4718-4718

2005

Volltextzugriff (PDF)

Bilan de la transfusion autologue programmee pour prelevement de moelle osseuse

Annales françaises d'anesthésie et de réanimation, 1996, Vol.15 (6), p.969-969

1996

Volltextzugriff (PDF)

One- and Two-Month-Old Dog Puppies Exhibit Behavioural Synchronization with Humans Independently of Familiarity

Animals (Basel), 2022-11, Vol.12 (23), p.3356

2022

Volltextzugriff (PDF)

Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma

Annals of hematology, 2020-02, Vol.99 (2), p.379-380

2020

Volltextzugriff (PDF)

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Leukemia research, 2017-09, Vol.60, p.11-17

2017

Volltextzugriff (PDF)

High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study

British journal of haematology, 2013-07, Vol.162 (2), p.240-249

2013

Volltextzugriff (PDF)

Therapeutic impact and diagnostic performance of multiplex PCR in patients with malignancies and suspected sepsis

The Journal of infection, 2010-10, Vol.61 (4), p.335-342

2010

Volltextzugriff (PDF)

Multidisciplinary team meetings in cancerology: setting priorities for improvement

Bulletin du cancer, 2011-10, Vol.98 (9), p.989

2011

Volltextzugriff (PDF)

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study

Blood, 2019-11, Vol.134 (Supplement_1), p.494-494

2019

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(56)
Berichte
(3)
Reviews
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(13)
Hematology
(9)
Male
(9)
Female
(8)
Aged
(7)
Oncology
(7)
Adult
(6)
Middle Aged
(6)
Treatment Outcome
(6)
Aged, 80 And Over
(5)
Biological And Medical Sciences
(5)
Life Sciences
(5)
Medical Sciences
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Cancer
(4)
Hematologic And Hematopoietic Diseases
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Antineoplastic Agents
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bulletin De Correspondance Hellénique
(14)
Blood
(11)
Revue Des Études Anciennes
(5)
Annals Of Oncology
(3)
British Journal Of Haematology
(2)
Bulletin Du Cancer
(2)
Leukemia & Lymphoma
(2)
Leukemia Research
(2)
Médecine Palliative
(2)
Animals
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia

81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES

P640 Fatal viral opportunistic infections and Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment for a refractory Sezary syndrome

Paraneoplastic Acute Diffuse Encephalitis Revealing Hodgkin's Disease

Hémorragies multiples inattendues chez un patient sous anticoagulants

Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

PS993 DE NOVO ADULT ACUTE MYELOID LEUKEMIA PATIENTS DISPLAY AT DIAGNOSIS FUNCTIONAL DEREGULATION OF REDOX BALANCE CORRELATED WITH MOLECULAR SUBTYPES AND OVERALL SURVIVAL

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM

Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia

Maladie de Hodgkin de localisation orbitaire : à propos d'un cas

Value of Early Evaluation with FDG-PET for Follicular Lymphoma

Bilan de la transfusion autologue programmee pour prelevement de moelle osseuse

One- and Two-Month-Old Dog Puppies Exhibit Behavioural Synchronization with Humans Independently of Familiarity

Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma

Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study)

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study

Therapeutic impact and diagnostic performance of multiplex PCR in patients with malignancies and suspected sepsis

Multidisciplinary team meetings in cancerology: setting priorities for improvement

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Suchergebnisse filtern